Enveric Biosciences (ENVB) announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office. The U.S. Patent Nos. 11,845,727; 11,858,895; 11,891,359; 11,998,557 and 12,128,058 join four other patents previously announced, bringing the total to nine issued U.S. patents covering the EVM301 portfolio and its drug candidate library. Enveric’s Psybrary is a proprietary catalogue of over 1,000 tryptamine derivative molecules that incorporates receptor engagement and functional data to correlate structure with biological activity.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric announces positive pharmacology/safety data for Lead Product, EB-003
- Rising High: Village Farms acquires remaining interest in Leli Holland
- Enveric announces research on non-hallucinogenic EB-003 for anxiety, depression
- Enveric Biosciences files to sell 4.9M shares of common stock for holders